(Q48027252)

English

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).

scientific article published in December 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

pulmonary emphysema

1 reference

based on heuristic

inferred from title

Joachim Hans Ficker

10

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

15

object named as

Marek Sanak

1 reference

Europe PubMed Central

7 February 2018

Joanna Chorostowska-Wynimko

14

object named as

Joanna Chorostowska-Wynimko

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Riitta Mäkitaro

13

object named as

Riitta Mäkitaro

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

author name string

Noel G McElvaney

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Jonathan Burdon

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Mark Holmes

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Allan Glanville

4

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Peter A B Wark

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Philip J Thompson

6

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Paul Hernandez

7

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Jan Chlumsky

8

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Helmut Teschler

9

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Niels Seersholm

11

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Alan Altraja

12

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Paul I Stoicescu

16

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Eeva Piitulainen

17

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Oliver Vit

18

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Marion Wencker

19

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Michael A Tortorici

20

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Michael Fries

21

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Jonathan M Edelman

22

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Kenneth R Chapman

23

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

RAPID Extension Trial Group

24

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

publication date

1 December 2016

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

51-60

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The challenge of detecting alpha-1 antitrypsin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

PULMONARY EMPHYSEMA AND ALPHA1-ANTITRYPSIN DEFICIENCY.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of computed density and microscopic morphometry in pulmonary emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Volume correction in computed tomography densitometry for follow-up studies on pulmonary emphysema.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The St George's Respiratory Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(16)30430-1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/27916480

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48027252&oldid=1742158083"